Testing to Commence on Lexaria’s Patent-Pending Technology

Lexaria Corp. (CSE:LXX,OTCMKTS:LXRP) announced that Absorption Systems LP will begin third party in vitro tests using human intestinal tissue model to  evaluate the cannabidiol (CBD) permeability of its patent-pending technology, which infuses cannabinoid compounds within lipids.

As quoted in the press release:

The study will assess CBD permeability achieved with our proprietary ViPova(TM) tea formulation at multiple sampling time points compared to positive and negative controls under strict experimental conditions. In vitro testing using human tissue models can be preferable to animal testing since human cells can be used directly to provide species-specific permeability results.

It is generally accepted in pharmacological sectors that the bioavailability of any active ingredient is one of the most important factors determining its effects on the body. Enhanced bioavailability can be extremely useful and is highly valued for any useful molecule, including CBD and tetrahydrocannabinol (THC).

Lexaria expects to begin this testing in the near future and will report results when they are available in due course, expected within the next 3-4 months.

John Docherty, president of Lexaria, commented:

Although we cannot know in advance the outcome of such tests, the results have the potential to materially affect future outcomes for the Company. We have a wealth of anecdotal evidence from our growing ViPova(TM) customer base extolling the marked effects of our CBD-infused tea and we look forward to the outcome of this study to help quantify this in detail.

Click here to read the full Lexaria Corp. (OTCMKTS:LXRP) press release.